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We investigated bacterial findings from intraoperative tissue samples taken during revision due to infection after total hip
arthroplasty (THA). The aim was to investigate whether the susceptibility patterns changed during the period from 1993 through
2007. Reported revisions due to infection in the Norwegian Arthroplasty Register (NAR) were identified, and 10 representative
hospitals in Norway were visited. All relevant information on patients reported to the NAR for a revision due to infection, including
bacteriological findings, was collected from the medical records. A total of 278 revision surgeries with bacterial growth in more
than 2 samples were identified and included. Differences between three 5-year time periods were tested by the chi-square test for
linear trend. The most frequent isolates were coagulase-negative staphylococci (CoNS) (41%, 113/278) and Staphylococcus aureus
(19%, 53/278). The proportion of CoNS resistant to the methicillin-group increased from 57% (16/28) in the first period, 1993–
1997, to 84% (52/62) in the last period, 2003–2007 (P = 0.003). There was also significant increase in resistance for CoNS to
cotrimoxazole, quinolones, clindamycin, and macrolides. All S. aureus isolates were sensitive to both the methicillin-group and
the aminoglycosides. For the other bacteria identified no changes in susceptibility patterns were found.
1. Introduction
Thedevelopment of bacterial resistance has been an emerging
problem since the introduction of the first antibiotics [1].
Studies of prosthetic joint infections (PJIs) have shown a high
prevalence of methicillin-resistant Staphylococcus aureus
(MRSA), methicillin-resistant Staphylococcus epidermidis
(MRSE), extended-spectrumbeta-lactamase-resistantGram-
negative bacteria (ESBL), and other highly resistant bacteria
in PJI [2, 3].
Norway has a lower incidence of highly resistant bacteria
compared to most European countries, but in selected pop-
ulations, such as intensive care unit patients with infected
foreign bodies (e.g., central venous catheters), an increasing
proportion of infections are caused byMRSE [4, 5]. PJIs, such
as an infected total hip arthroplasty (THA), impose a burden
to the affected patients and are difficult to treat. An increased
risk of revision due to deep infection after THA has been
found inNorway as in the other Nordic countries [6, 7]. It has
been suggested that increased bacterial resistance may have
contributed to the increased risk of revision due to infection
[8].
The aim in the present study was to investigate whether
the susceptibility patterns had changed during the observa-
tion period from 1993 through 2007 for the bacteria causing
deep infection after THA in Norway.
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Figure 1: Flowchart showing the selection of patients.
2. Material and Methods
Since its inception in 1987,The Norwegian Arthroplasty Reg-
ister (NAR) has collected individual information on primary
and revision THA [9]. Based on preoperative clinical exam-
inations, laboratory tests, and intraoperative findings, the
reason for revision is reported immediately after surgery by
the surgeon to the NAR. The patients in this study were
reported as revisions for infections. Bacterial findings were
not reported to the NAR.
Patients from the period January 1, 1993, to September 30,
2007, were included. The study period was divided into three
5-year periods, which were compared to evaluate possible
changes of resistance during the study period.
Based on registrations in the NAR, the ten hospitals with
most THA-revisions due to infection, spread all over Norway,
were visited by a single observer. This reflects large volumes
of surgery, not higher rates of infection. Revision was defined
as exchange or removal of parts or the whole prosthesis.
For capacity reasons, we had to limit the number of visited
hospitals to ten.These hospitals reported half of the revisions
for infected THAs in the study period. Bacterial findings and
susceptibility charts from the medical records were collected
(Figure 1). To be included, the clinical diagnosis of infection
had to be verified by two or more intraoperative tissue
Table 1: Patient characteristics.
Variable
Sex (%)
Male 32,4
Female 67,6
Age (mean) (SD) 69,4 (10,9)
Diagnosis (%)
Osteoarthritis 67,3
Inflammatory 4,0
Other 28,7
Antibiotic prophylaxis systemically (%)
Yes 98,4
No 1,6
Method of fixation (%)
Uncemented 11,1
Cement
With antibiotics 72,2
Without antibiotics 16,7
samples with valid growth of the same bacteria. Identification
of the bacteria also had to include susceptibility panels. The
tissue samples were handled fresh; mostly five samples were
taken. There was no sonicated prosthesis included, as this
method was, and still is not, in routine use in Norway. Thus,
revisions reported as infections, but with no growth in intra-
operative tissue samples, were not included (𝑛 = 139). These
were mostly cases in which the patients had received antibi-
otics prior to surgery.
278 patients met the inclusion criteria. Patient character-
istics are described in Table 1.
In addition, awritten survey from all Norwegianmicrobi-
ology laboratories was performed, asking about their culture
techniques and growth media, incubation time, susceptibil-
ity panels, and breakpoints. In 2007, all the microbiology
laboratories followed the recommendations for susceptibility
patterns and breakpoints determining S, I, and R (SIR =
Sensitive, Intermediate, Resistant) for the different bacteria,
as recommended by the AFA (the Norwegian workgroup for
questions regarding antibiotics). However, during the study
period, the laboratories changed the susceptibility panels
from 1, 2, 3, and 4 to SIR. We transformed 1 as S, 2 and 3 as I,
and 4 as R. SIRwas dichotomized into either S or R, regarding
I as R to separate the sensitive bacteria from the rest.
The laboratories had, to some extent, used different
methods, susceptibility panels, and incubation times over the
15 years studied. The mean incubation period was 7 days in
2007.
In general, few of the cultures were tested against line-
zolid, carbapenems, and rifampicin because those antibiotics
were not part of the standard susceptibility panels used in
Norway during the study period. In addition, few staphylo-
cocci were tested against the quinolones because the Norwe-
gian regulatory authorities do not want the quinolones avail-
able in Norway (ciprofloxacin and ofloxacin) to be used rou-
tinely in the treatment of Gram-positive infections, in order
to avoid the development of resistance.
Advances in Orthopedics 3
We chose to combine methicillin, oxacillin, and cloxa-
cillin in one group called the methicillin group. The labo-
ratories used one of the above as a marker for resistance
towards cloxacillin, dicloxacillin, and all cephalosporins.
Furthermore, we combined the aminoglycosides gentamicin,
tobramycin, and netilmicin into one aminoglycoside group.
Ciprofloxacin and ofloxacin were combined in the quinolone
group. Imipenem and meropenem were combined in the
carbapenem group. Ceftazidime, ceftriaxone, and cefotaxime
were combined in the third generation cephalosporin group.
The study was approved by the Regional Committee for
Medical Research Ethics (number 2009/856b).
The chi-square test for linear trend was used to evaluate
changes over time in the distribution of resistance. 𝑃 values
less than 0.05 were considered significant. Statistical analyses
were performed using SPSS version 20 (SPSS Inc., 2004).
3. Results
The distribution of bacteria isolates is presented in Table 2.
Coagulase-negative staphylococci (CoNS) were the dominat-
ing bacteria (41%), followed by S. aureus (19%).The results for
antibiotic susceptibility are summarized in Table 3.
3.1. Coagulase-Negative Staphylococci. We found a high prop-
ortion of resistant strains among CoNS. Resistance increased
with time. All CoNS cultures retained full susceptibility only
to linezolid (only tested the last years) and vancomycin.
Resistance significantly increased over time to the methi-
cillin group (𝑃 = 0.003), clindamycin (𝑃 = 0.048), trime-
thoprim/sulfamethoxazole (cotrimoxazole) (𝑃 = 0.03),
quinolones (𝑃 = 0.03), and macrolides (𝑃 = 0.03). A trend of
increased resistance was seen for aminoglycosides (𝑃 = 0.15)
(Figure 2). Only a few rifampicin-resistant strains were iden-
tified, and only during the last 5-year period.
3.2. Staphylococcus aureus. All S. aureus cultures were susce-
ptible to aminoglycosides, the methicillin group, rifampicin,
vancomycin, linezolid, and cotrimoxazole. A few strains were
found to be resistant to fusidic acid, clindamycin, quinolones,
and macrolides.
3.3. Streptococci. All streptococci were susceptible to peni-
cillin. A few strains were found to be resistant to clindamycin
and macrolides.
3.4. Enterococci. All enterococci were susceptible to linezolid
and vancomycin, and only one was resistant to ampicillin.
However, a large proportion of the enterococci were resistant
to aminoglycosides throughout the study period. We did not
have information on whether some of the enterococci were
highly resistant, so-called high-level gentamicin-resistant
enterococci (HLGRE).
3.5. Gram-Negative Bacteria. The Gram-negative bacteria
were all but one susceptible to aminoglycosides. A few strains
were resistant to quinolones; a large proportion of the strains
were resistant to ampicillin.
Table 2: Type of bacteria.
Frequency Percent
Coagulase-negative staphylococci 113 41
Staphylococcus aureus 53 19
Streptococci 30 11
Enterococci 26 9
Gram-negative bacteria 17 6
Polymicrobial 27 10
Other microbes 12 4
Total 278 100
4. Discussion
We found a high proportion of resistant strains amongCoNS,
and we found that resistance increased with time.
Formany years, CoNSwere considered incapable of caus-
ing serious clinical infection and discarded as contamination
when found in periprosthetic tissue cultures. However, CoNS
are now considered amajor cause of PJI [8, 10].We found that
CoNS was the most frequent bacteria causing infected THA
in Norway.
The CoNS are skin commensals. When found in patients
outside hospital settings, these bacteria exhibit less antimi-
crobial resistance than bacteria isolated from hospitalized
patients and hospital personnel. Rapid transformation from
susceptible to resistant strains has been shown soon after
patients have been hospitalized [11–13]. Pre- and postopera-
tive hospitalization for primaryTHAmayhave influenced the
finding of a high proportion of multidrug resistant CoNS, as
could the extensive use of cement containing antibiotics.
We do not know if the increased proportion of resistant
CoNS is due to a general transformation of the bacterial flora,
or if it only reflects a selection of bacteria causing THA infec-
tion. Epidemiologic surveys of CoNS susceptibility are absent
in Norway.
The emergence of drug resistance in CoNS has been
shown to reflect the consumption of antibiotics [14, 15]. We
do not have data on the use of antibiotics for each individual
patient, except for prophylaxis in primary THA as reported to
theNAR.TheNorwegian Institute of Public Health has found
an increase in the use of both cephalosporins and quinolones
in Norway during our study period [16]. This may also have
contributed to the increased resistance of CoNS found in
infected THA.
Other studies of PJI in hip- and knee arthroplasty have
found the proportion of MRSE among bacterial infections to
be 62–72% [2, 3, 17, 18]. Our findings of 70%MRSE are similar
to these findings.
Dale et al. found a 3-fold increased risk of revision due
to THA infection during the time period 2003–2007 com-
pared to the time period 1987–1992 [6]. In an editorial com-
ment to Dale’s paper, Walenkamp raised the question of
whether increased bacterial resistance could be part of the
explanation [8]. Our findings support Walenkamp’s opinion
that increased prevalence of MRSE could be a part of the
explanation.
4 Advances in Orthopedics
Ta
bl
e
3:
Su
sc
ep
tib
ili
ty
to
se
le
ct
ed
an
tib
io
tic
s,
gi
ve
n
as
nu
m
be
ro
ft
es
te
d
iso
lat
es
su
sc
ep
tib
le
to
th
eg
iv
en
an
tib
io
tic
/to
ta
ln
um
be
rt
es
te
d.
C
oN
S
S.
au
re
us
En
te
ro
co
cc
i
G
ra
m
-n
eg
at
iv
e
St
re
pt
oc
oc
ci
Ti
m
ep
er
io
d
(y
ea
rs
)
93
–9
7
98
–0
2
03
–0
7
93
–9
7
98
–0
2
03
–0
7
93
–9
7
98
–0
2
03
–0
7
93
–9
7
98
–0
2
03
–0
7
93
–9
7
98
–0
2
03
–0
7
A
m
in
og
ly
co
sid
es
10
/19
13
/2
6
14
/4
5
5/
5
8/
8
22
/2
2
0/
8
0/
2
3/
10
4/
4
7/
8
11
/11
M
et
hi
ci
lli
n
gr
ou
p
12
/2
8
15
/3
3
10
/6
2
10
/10
15
/15
37
/3
7
C
ep
ha
lo
sp
or
in
s,
3r
d
ge
ne
ra
tio
n
2/
3
6/
6
6/
7
Cl
in
da
m
yc
in
23
/2
9
17
/3
1
34
/6
4
11
/11
13
/13
35
/3
6
2/
2
6/
6
10
/13
Q
ui
no
lo
ne
s
6/
6
8/
17
8/
20
2/
2
0/
4
3/
4
2/
3
4/
7
8/
10
Ca
rb
ap
en
em
s
3/
3
4/
5
8/
8
Li
ne
zo
lid
3/
3
38
/3
8
11
/11
1/1
10
/10
Ri
fa
m
pi
ci
n
4/
4
3/
3
22
/2
6
1/1
6/
6
Fu
sid
ic
ac
id
12
/2
9
14
/3
1
33
/6
3
11
/11
13
/14
33
/3
5
M
ac
ro
lid
es
16
/2
0
9/
22
29
/5
7
7/
7
11
/12
32
/3
3
3/
3
5/
6
8/
11
C
ot
rim
ox
az
ol
e
10
/16
10
/18
12
/4
1
4/
4
7/
7
24
/2
4
3/
3
5/
7
9/
9
A
m
pi
ci
lli
n
9/
9
3/
4
20
/2
0
1/4
4/
9
1/1
0
Pe
ni
ci
lli
n
5/
5
8/
8
15
/15
Va
nc
om
yc
in
26
/2
6
23
/2
3
51
/5
1
8/
8
7/
7
10
/10
6/
6
3/
3
15
/15
C
oN
S
=
co
ag
ul
as
e-
ne
ga
tiv
es
ta
ph
yl
oc
oc
ci
.
Advances in Orthopedics 5
0
10
20
30
40
50
60
70
80
90
1993–1997 1998–2002 2003–2007
(%
)
The methicillin group(1)
(a)
1993–1997 1998–2002 2003–2007
0
10
20
30
40
50
(%
)
Clindamycin(1)
(b)
1993–1997 1998–2002 2003–2007
0
10
20
30
40
50
60
70
80
(%
)
Cotrimoxazole(1)
(c)
1993–1997 1998–2002 2003–2007
0
10
20
30
40
50
60
70
80
(%
)
Aminoglycosides(2)
(d)
Figure 2: Development of resistance in coagulase-negative staphylococci towards selected antibiotics. Percent resistance is present on the
𝑦-axis, time period on the 𝑥-axis. (1) Significant increase in resistance for methicillin, clindamycin, and cotrimoxazole (𝑃 < 0.05). (2) Not
significant increase in resistance for aminoglycosides (𝑃 = 0.15).
We found a high proportion of CoNS and enterococci
resistant to the aminoglycosides. A trend towards increasing
aminoglycoside resistancewas foundwithCoNS,whereas the
resistance was more or less unchanged for the other bacteria.
Interestingly, Fulkerson found a higher rate of susceptible
CoNS for aminoglycosides in a cohort from New York and
Chicago (87%) compared to our Norwegian patients (51%)
[19]. The explanation for this difference could be that in
Norway gentamicin-loaded bone cement was used in most
primary THAs. In contrast, in the United States cementless
implants are predominant, and when bone cement is used in
primary surgery, it mostly does not contain antibiotics [20].
We found no methicillin-resistant S. aureus (MRSA). In
Norway, there is a very low incidence of MRSA compared
to most other countries [4]. In an English study, an MRSA
prevalence of 8% was found. In a study from Australia, a
prevalence of 11%MRSAwas found (6/53) [2, 3]. In a Swedish
study of infected knee implants only 1/84 of the causal
bacteria were MRSA, reflecting the low incidence of MRSA
also in another Scandinavian country [17]. The favorable
resistance patterns of S. aureus are also reflected by the lack
of resistance to aminoglycosides, linezolid, rifampicin, cotri-
moxazole, and quinolones, and only sporadic cases of resis-
tance to macrolides, clindamycin, and fusidic acid.
The incidence ofmethicillin resistance is higher for CoNS
than S. aureus. In Norway, strict measures have been taken to
prevent the spread of MRSA, similar to the Netherlands, and
these programs have been successful thus far [21]. Preventing
the spread of MRSE has proven more difficult [22].
Limitations. The present study has some limitations. It is a
retrospective study based on data from a national registry.
However, our data on revisions due to infection after THA
were prospective, and the NAR has been found to have good
completeness [23, 24]. Since we used the NAR to identify
cases of infection for the purpose of collecting bacteriological
data, and the hospitals were different in types and spread all
over the country, we expect the selection bias to be minor.
Hence, we assume that our findings are representative for the
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susceptibility patterns with bacteria causing infected THAs in
Norway over the study period.
The diagnosis of infection was based on perioperative
assessment by the orthopaedic surgeon, before culturing
results of intraoperative tissue samples were available. Since
only cases with growth of the same bacteria in two or more
tissue samples were included, all revisions included in the
present study should be true PJIs. However, these strict crite-
ria led to a high amount of reported revisions disqualified due
to no growth or only one positive sample. We did not include
preoperative joint fluid collection, as we first and foremost
wanted our included revisions to be true PJIs, and we wanted
full susceptibility charts. Also, PJIs treated with debridement
without change of liner or head, or antibiotic suppression
therapy alone, were not reported to the NAR and thus not
included in the present study.
Clinical Implications. In Norway, the common practice is to
use cephalothin as systemic prophylaxis during surgery and
gentamicin in bone cement as local prophylaxis for cemented
THAs [25]. The most common empirical antibiotic therapy
for suspected PJI has been a combination of cloxacillin and
gentamicin.With 84%methicillin resistance and 67% amino-
glycoside resistance for CoNS during the last time period,
treatment failure could be the result of inadequate antibiotic
coverage. Thus, preoperative sampling, such as aspiration or
biopsy, is crucially important, especially in low-grade infec-
tions. Under these circumstances, the patients are normally
nonseptic, and there is time to await the culture results before
surgical and medical treatment of the infection. The second
most commonpathogen, S. aureus, is fully susceptible to both
the prophylactic regimen and the empirical treatment.
The antibiotic treatment must be adjusted to the bacteri-
ological findings. When MRSE is proven or likely the cause
of infection, vancomycin should be added to bone cement or
spacers if used in revision surgery and should also be part
of the systemic treatment [26]. The newly published national
guidelines for use of antibiotics in hospitals from The Nor-
wegian Directorate of Health have now advocated the use of
vancomycin as empirical treatment for PJI, partly based on
data from our study [27].
5. Conclusion
We identified an increase in the proportion of PJI-causing
methicillin-resistant CoNS over the study period. Adequate
bacterial sampling is crucial for choosing the right antibiotic
treatment. This is increasingly important given the emerging
resistance of CoNS found in PJI in the present study.
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